TaiMed Biologics, a global leader in HIV drug development, will showcase its remarkable achievements at the Asia Biotechnology Conference from July 25-28, 2024:
 
  1. Trogarzo: The world’s only approved monoclonal antibody therapy for HIV.
  2. TMB-365/380: An innovative therapy featuring a long-acting dual antibody combination.
  3. Antibody Drug Conjugate (ADC) Technology Platform: The world's first for HIV treatment.
  4. CDMO Business at Zhubei Plant.

Trogarzo, the world’s only commercialized monoclonal antibody therapy for HIV, has revolutionized the treatment landscape, providing a new therapeutic option for patients with multi-drug-resistant HIV, enhancing both efficacy and safety. Building on this success, TaiMed Biologics is focusing on the development of the long-acting dual antibody combination TMB-365/380, which is currently in Phase II(a) clinical trials, with progress already over halfway. This new therapy aims to capture a significant portion of the $10 billion first-line long-acting maintenance therapy market.

Moreover, the world-first ADC technology platform from TaiMed Biologics promises to be a revolutionary innovation in HIV treatment. ADC combines the precise targeting capability of monoclonal antibodies with the potent effectiveness of antiretroviral drugs. Compared to cancer treatment ADCs, TaiMed’s ADC technology features a triple-action mechanism: (i) serving as a carrier for antiretroviral drugs, and (ii) acting as an effective HIV entry inhibitor, (iii) precision antiretroviral activity. This three-in-one effect, combining precision targeting, antiviral drug delivery, and HIV entry inhibition, could significantly enhance therapeutic efficacy.

Latest Business Updates:
  1. TMB-365/380 Phase II(a) Trial Progress and Results
The long-acting dual antibody combination TMB-365/380 is administered every two months. All participants have completed the second injection and have started receiving the third. The final participant is expected to complete all three doses by early September. Results are anticipated by late 2024 to early 2025. So far, all participants have responded well, with sustained viral load suppression and no significant adverse events reported.
 
  1. Active Participation in International Conferences
The CEO of TaiMed Biologics has actively participated in several international conferences, including the J.P. Morgan Healthcare Conference in San Francisco, the Asia Bio Partnering Forum in Singapore, and the BIO International Convention 2024 in San Diego. These engagements are focused on discussions regarding licensing and partnerships for commercialized Trogarzo in additional global territories, ongoing projects such as TMB-365/380, and ADC technology, as well as CDMO services. Discussions with potential partners continue, with TMB-365/380 expected to generate licensing revenues significantly higher than Trogarzo based on the US$10 billion long-acting market potential.
 
  1. HIV Treatment Market Growth
According to a report by Precedence Research in May 2024, the global HIV drug market was valued at US$33.92 billion in 2023 and is projected to grow at a compound annual growth rate of 4.3%, reaching US$49.68 billion by 2032. The market share of long-acting treatment drugs is expected to increase significantly from the current 3% to 40%, becoming the mainstream. Preventive medications, primarily used for high-risk groups with limited impact due to the necessity of national medical funding support, are estimated to occupy about 5% of the market.
 
  1. Trogarzo Sales Expansion
TaiMed Biologics has signed licensing agreements with AcedrA for the MENA region, with Wuzhou Pharmaceuticals for Hong Kong and Macau, and with OEP Biotechnology for Taiwan. The companies are preparing to submit regulatory filings in these regions, with local market launches expected from the second half of 2025 onwards, projecting significant sales growth in 2025.
 
  1. Positive Cash Flow from Operations
In the first half of 2024, TaiMed Biologics had a cash balance of approximately NT$2.1 billion. The second quarter saw a net cash inflow of about NT$30 million, marking the second consecutive quarter of positive cash flow from operations. The first quarter also saw the completion of a NT$1.64 billion capital raise, boosting the net asset value per share to over NT$15 and significantly improving the company’s financial structure. This financial health supports the completion of Phase II trials and facilitates TMB-365/380 licensing preparations.
 
  1. ADC New Drug Development Progress
The innovative ADC R&D program has completed in vitro proof-of-concept studies, with highly promising data. The company is optimizing linker stability before proceeding to animal studies. Additionally, in June 2024, TaiMed Biologics filed for patent protection of this ADC technology in the US, Taiwan, and other major global markets.
 
  1. Collaboration with Taiwan Lourdes Association
TaiMed Biologics is partnering with the renowned HIV advocacy group Taiwan Lourdes Association to promote HIV education during the biotechnology exhibition. This collaboration includes informational seminars and video presentations to raise public awareness about HIV, fulfilling the company’s corporate social responsibility.

TaiMed Biologics looks forward to engaging with industry partners at this biotechnology exhibition, driving progress and innovation in HIV treatment.
 
Back to the top